Physician profile
John C Pearson
NPI 1497731343
$1,949.17
in general payments reported to CMS, 2019-2025
17 companies · $281 in 2025
The $281 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $315 · 2021: $129 · 2022: $28.42 · 2023: $53.29 · 2024: $66.98 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $517.76 | 2021-2025 | Interstim |
| Astellas Pharma US INC | $328.16 | 2019-2020 | |
| Janssen Biotech, INC. | $218.27 | 2019-2020 | |
| Amgen INC. | $138.27 | 2019 | |
| Boston Scientific Corporation | $107.18 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.15 | 2019-2020 | |
| Cook Medical LLC | $105.22 | 2019 | |
| Dendreon Pharmaceuticals LLC | $104.96 | 2019-2020 | |
| Pfizer INC. | $62.58 | 2019-2020 | |
| Abbvie INC. | $57.82 | 2019 | |
| Ferring Pharmaceuticals INC. | $56.59 | 2019 | |
| Duchesnay USA Incorporated | $48.89 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $40.84 | 2019 | |
| Axonics, INC. | $36.74 | 2020 | |
| Endo Pharmaceuticals INC. | $18.74 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.